IP Library › Granted Patent US 11,773,055
Granted Patent B2
US 11,773,055 · App. 17/673,381 · Granted Oct 3, 2023

Chemical derivatives and methods for synthesizing and compounding chemical derivatives related to capsaicin palmitate and capsaicin prodrugs

Inventors: Richard Daniel Carliss (Roanoke, VA); Jianxing William Huang (Betlehem, PA)
Assignee: CHORDA PHARMA, INC.
C07C271/40C07C271/06C07D295/205C07D295/215
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,773,055
App. No.
17/673,381
Granted
Oct 3, 2023
Kind
B2
Abstract

Capsaicin compositions and methods for enhancing hydrophobicity of a molecule useful for pharmaceutical applications, including: (1) a prodrug using a linker such as a carbamate between capsaicin with other structures in order to optimize kinetic control of capsaicin cleavage; (2) a prodrug using a linker such as an unsaturated carboxylic ester between capsaicin with other structures in order to optimize kinetic control of capsaicin cleavage; (3) esters of long-chain fatty acids and capsaicin where hydroxyl groups provide handles for attachment of additional capsaicin molecules; and (4) the use of carboxylic acid diesters to increase overall hydrophobicity of two or more covalently-linked capsaicin molecules. Formulations of palmitated esters of capsaicin are also described, which are designed to enhance hydrophobicity of a molecule useful for pharmaceutical applications, for example to provide compounded mixtures designed to optimize analgesic efficacy.

Claims (171)

1. A prodrug having a structure of formula (I), (II), (III), (IV), (V), (VI), (VII), (VII-A), (X), (XI) or (XII):

(a)

wherein:

Cpsn represents a capsaicinoid,

X is CH or N,

R is H or C(O)R′ where R′ is a C 1-20 hydrocarbon,

when X is CH, m is 1 to 3, and n is 0 to 2,

when X is N, m is 2, and n is 2, and

the capsaicinoid is joined at a free phenolic hydroxyl group via the carbamate-containing linkage of formula (I);

(b)

wherein:

Cpsn represents a capsaicinoid,

X is CH or N,

m is 1 to 3,

n is 0 to 2,

when X is CH,

m is 1 to 3,

n is 0, and

R is OH or OR′ where R′ is a C 1-20 hydrocarbon, a molecule with analgesic properties, or a molecule with pharmacological properties,

when X is N, and n is 0,

m is 2, and

R is a C 1-20 hydrocarbon,

when X is N, and n is 1 or 2,

m is 2, and

R is OH or OR′ where R′ is a C 1-20 hydrocarbon, a molecule with analgesic properties, or a molecule with pharmacological properties, and

the capsaicinoid is joined at a free phenolic hydroxyl group via the carbamate-containing linkage of formula (II);

(c)

wherein:

Cpsn represents a capsaicinoid,

X is CH,

R is H or C(O)R′ where R′ is a C 1-20 hydrocarbon,

m is 1 to 2,

n is 1 to 2, and

the capsaicinoid is joined at a free phenolic hydroxyl group via the carbamate-containing linkage of formula (III);

(d)

wherein:

Cpsn represents a capsaicinoid,

X is CH,

R is H or C(O)R′ where R′ is a C 1-20 hydrocarbon,

m is 0 to 2, and

the capsaicinoid is joined at a free phenolic hydroxyl group via the carbamate-containing linkage of formula (IV);

(e)

wherein:

Cpsn represents a capsaicinoid,

X is CH,

R is H, a C 1-20 hydrocarbon, a molecule with analgesic properties, or a molecule with pharmacological properties,

m is 1 to 2, and

the capsaicinoid is joined at a free phenolic hydroxyl group via the carbamate-containing linkage of formula (V);

(f)

wherein:

Cpsn represents a capsaicinoid,

X is CH,

R is H, a C 1-20 hydrocarbon, a molecule with analgesic properties, or a molecule with pharmacological properties,

m is 1 to 2, and

the capsaicinoid is joined at a free phenolic hydroxyl group via the carbamate-containing linkage of formula (VI);

(g)

wherein:

Cpsn represents a capsaicinoid,

X is an -sp 3 - or -sp 2 -hybridized carbon (C),

m is 1 to 2,

n is 1 to 2,

each Y is F, or both Y together represent ═O, and

the capsaicinoid is joined at a free phenolic hydroxyl group via the carbamate-containing linkage of formula (VII);

(h)

wherein:

Cpsn represents a capsaicinoid,

n is 1 to 2,

m is 1 to 2, and

the capsaicinoid is joined at a free phenolic hydroxyl group via the carbamate-containing linkage of formula (VII-A);

(i)

wherein:

Cpsn represents a capsaicinoid,

X, Y, and Z are C, or two of X, Y, and Z are N and the remaining one of X, Y, Z is CH; and

the capsaicinoid is joined a free phenolic hydroxyl group via the carbamate-containing linkage of formula (X);

(j)

wherein

Cpsn represents a capsaicinoid;

n is 0 to 2;

R is H or C(O)R′ where R′ is a C 1-20 hydrocarbon; and

the capsaicinoid is joined at a free phenolic hydroxyl group via the carbamate-containing linkage of formula (XI); or

(k)

wherein:

Cpsn represents a capsaicinoid;

R is OH or OR′ where R′ is a C 1-20 hydrocarbon, a molecule with analgesic properties, or a molecule with pharmacological properties; and

the capsaicinoid is joined at a free phenolic hydroxyl group via the carbamate-containing linkage of formula (XII).

2. The prodrug of claim 1 having the structure of formula (I):

wherein:

Cpsn represents the capsaicinoid;

X is CH or N;

R is H or C(O)R′ where R′ is a C 1-20 hydrocarbon;

when X is CH, m is 1 to 3, and n is 0 to 2;

when X is N, m is 2, and n is 2; and

the capsaicinoid is joined at the free phenolic hydroxyl group via the carbamate-containing linkage of formula (I).

3. The prodrug of claim 1 having the structure of formula (II):

wherein

Cpsn represents the capsaicinoid;

X is CH or N;

m is 1 to 3;

n is 0 to 2;

when X is CH,

m is 1 to 3,

n is 0, and

R is OH or OR′ where R′ is a C 1-20 hydrocarbon, a molecule with analgesic properties, or a molecule with pharmacological properties;

when X is N, and n is 0,

m is 2, and

R is a C 1-20 hydrocarbon;

when X is N, and n is 1 or 2,

m is 2, and

R is OH or OR′ where R′ is a C 1-20 hydrocarbon, a molecule with analgesic properties, or a molecule with pharmacological properties; and

the capsaicinoid is joined at the free phenolic hydroxyl group via the carbamate-containing linkage of formula (II).

4. The prodrug of claim 1 having the structure of formula (III):

wherein:

Cpsn represents the capsaicinoid;

X is CH;

R is H or C(O)R′ where R′ is a C 1-20 hydrocarbon;

m is 1 to 2;

n is 1 to 2; and

the capsaicinoid is joined at the free phenolic hydroxyl group via the carbamate-containing linkage of formula (III).

5. The prodrug of claim 1 having the structure of formula (IV):

wherein:

Cpsn represents the capsaicinoid;

X is CH;

R is H or C(O)R′ where R′ is a C 1-20 hydrocarbon;

m is 0 to 2; and

the capsaicinoid is joined at the free phenolic hydroxyl group via the carbamate-containing linkage of formula (IV).

6. The prodrug of claim 1 having the structure of formula (V):

wherein:

Cpsn represents the capsaicinoid;

X is CH;

R is H, a C 1-20 hydrocarbon, a molecule with analgesic properties, or a molecule with pharmacological properties;

m is 1 to 2; and

the capsaicinoid is joined at the free phenolic hydroxyl group via the carbamate-containing linkage of formula (V).

7. The prodrug of claim 1 having the structure of formula (VI):

wherein:

Cpsn represents the capsaicinoid;

X is CH;

R is H, a C 1-20 hydrocarbon, a molecule with analgesic properties, or a molecule with pharmacological properties;

m is 1 to 2; and

the capsaicinoid is joined at the free phenolic hydroxyl group via the carbamate-containing linkage of formula (VI).

8. The prodrug of claim 1 having the structure of formula (VII):

wherein:

Cpsn represents the capsaicinoid;

X is an -sp 3 - or -sp 2 -hybridized carbon (C);

m is 1 to 2;

n is 1 to 2;

each Y is F, or both Y together represent ═O; and

the capsaicinoid is joined at the free phenolic hydroxyl group via the carbamate-containing linkage of formula (VII).

9. The prodrug of claim 1 having the structure of formula (X):

wherein:

Cpsn represents the capsaicinoid;

X, Y, and Z are CH, or two of X, Y, and Z are N and the remaining one of X, Y, and Z is CH; and

the capsaicinoid is joined at the free phenolic hydroxyl group via the carbamate-containing linkage of formula (X).

10. The prodrug of claim 1 having the structure of formula (VII-A):

wherein:

Cpsn represents the capsaicinoid;

n is 1 to 2;

m is 1 to 2; and

the capsaicinoid is joined at the free phenolic hydroxyl group via the carbamate-containing linkage of formula (VII-A).

11. A composition, comprising a prodrug of claim 1 and an inactive ingredient.

12. The composition of claim 11 , wherein the inactive ingredient is at least one selected from the group consisting of water, an oil, a surfactant, an emulsifier, a stabilizer, a chelator, a preservative, and a pH-adjusting agent.

13. The prodrug of claim 1 having the structure of formula (XI):

wherein:

Cpsn represents a capsaicinoid;

n is 0 to 2;

R is H or C(O)R′ where R′ is a C 1-20 hydrocarbon; and

the capsaicinoid is joined at the free phenolic hydroxyl group via the carbamate-containing linkage of formula (XI).

14. The prodrug of claim 1 having the structure of formula (XII):

wherein:

Cpsn represents a capsaicinoid;

R is OH or OR′ where R′ is a C 1-20 hydrocarbon, a molecule with analgesic properties, or a molecule with pharmacological properties; and

the capsaicinoid is joined at the free phenolic hydroxyl group via the carbamate-containing linkage of formula (XII).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 17, 2022
From: CARLISS, RICHARD DANIEL; HUANG, JIANXING WILLIAM
To: CHORDA PHARMA, INC.
Reel/Frame 059030/0211 →
Continuity (3)
Continuation PCTUS2020046861 · Aug 18, 2020
Provisional Application 62889002 · Aug 19, 2019
Related Publication 20220168259A1 · Jun 2, 2022